{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:51:37Z","timestamp":1789674697933,"version":"4.0.1"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ctrv.2026.103143","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:31:33Z","timestamp":1777523493000},"page":"103143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Progress toward personalized management of stage II\/III triple negative breast cancer"],"prefix":"10.1016","volume":"147","author":[{"given":"Irene","family":"Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana M","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Werutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-0991","authenticated-orcid":false,"given":"Elie","family":"Rassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103143_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103143_b0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2023.25881","article-title":"Analysis of Breast Cancer Mortality in the US-1975 to 2019","volume":"331","author":"Caswell-Jin","year":"2024","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2026.103143_b0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.2023.26730","article-title":"Benefits of Breast Cancer Screening and Treatment on Mortality","volume":"331","author":"Wheeler","year":"2024","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2026.103143_b0020","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds187","article-title":"Triple-negative breast cancer: epidemiological considerations and recommendations","volume":"23","author":"Boyle","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.22836","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute\u2019s Surveillance, Epidemiology, and end results database","volume":"110","author":"Morris","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0030","doi-asserted-by":"crossref","first-page":"e4614","DOI":"10.1097\/MD.0000000000004614","article-title":"Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database","volume":"95","author":"Plasilova","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ctrv.2026.103143_b0035","doi-asserted-by":"crossref","unstructured":"Adrada, B.E., Moseley, T.W., Kapoor, M.M., Scoggins, M.E., Patel, M.M., Perez, F., Nia, E.S., Khazai, L., Arribas, E., Rauch, G.M., et al. (2023). Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment. Radiogr. Rev. Publ. Radiol. Soc. N. Am. Inc 43, e230034. Doi: 10.1148\/rg.230034.","DOI":"10.1148\/rg.230034"},{"key":"10.1016\/j.ctrv.2026.103143_b0040","article-title":"Racial and regional disparities of triple negative breast cancer incidence rates in the United States: an analysis of 2011\u20132019 NPCR and SEER incidence data","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.ctrv.2026.103143_b0045","unstructured":"Manzano, A., and Hofmarcher, T. Improving the care of women with triple-negative breast cancer."},{"key":"10.1016\/j.ctrv.2026.103143_b0050","doi-asserted-by":"crossref","first-page":"10865","DOI":"10.1002\/cam4.5792","article-title":"Disparities in stage at diagnosis among breast cancer molecular subtypes in China","volume":"12","author":"Zeng","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103143_b0055","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/jso.28088","article-title":"Disparities in Triple negative Breast Cancer among Hispanic Population living in Latin America Versus the United States","volume":"131","author":"De la Cruz Ku","year":"2025","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0060","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0065","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/annonc\/mdp492","article-title":"Triple-negative breast cancer\u2013current status and future directions","volume":"20","author":"Gluz","year":"2009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0070","article-title":"Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis","volume":"2015","author":"Zhang","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ctrv.2026.103143_b0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.2012-0397","article-title":"Molecular characterization of basal-like and non-basal-like triple-negative breast cancer","volume":"18","author":"Prat","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103143_b0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103143_b0085","first-page":"2929","article-title":"Breast cancer intrinsic subtype classification, clinical use and future trends","volume":"5","author":"Dai","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0090","doi-asserted-by":"crossref","first-page":"10393","DOI":"10.1073\/pnas.1732912100","article-title":"Breast cancer classification and prognosis based on gene expression profiles from a population-based study","volume":"100","author":"Sotiriou","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.ctrv.2026.103143_b0095","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of Triple-negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2026.103143_b0105","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and Transcriptomic Landscape of Triple-negative Breast Cancers: Subtypes and Treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103143_b0110","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res","volume":"21","author":"Burstein","year":"2015","journal-title":"Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0115","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3390\/jpm11090881","article-title":"Molecular Classification Models for Triple negative Breast Cancer Subtype using Machine Learning","volume":"11","author":"Bissanum","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.ctrv.2026.103143_b0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into Molecular Classifications of Triple-negative Breast Cancer: improving Patient selection for Treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103143_b0125","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0135","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-LB1-07","article-title":"Abstract LB1-07: Exploratory Biomarker Analysis of the phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC","volume":"31","author":"O\u2019Shaughnessy","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0140","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-GS3-05","volume":"31","author":"Geyer","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0145","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdz395","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","volume":"30","author":"Park","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0150","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jamaoncol.2024.1917","article-title":"Tumor-Infiltrating Lymphocytes in patients with stage I Triple-negative Breast Cancer Untreated with Chemotherapy","volume":"10","author":"Geurts","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0155","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-Infiltrating Lymphocytes in Triple-negative Breast Cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2026.103143_b0160","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1200\/JCO.21.01536","article-title":"Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-negative, Triple-negative Breast Cancer patients who did not Receive (neo)Adjuvant Systemic Therapy","volume":"40","author":"de Jong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0165","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13058-024-01932-4","article-title":"Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer","volume":"26","author":"Han","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0170","doi-asserted-by":"crossref","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103143_b0175","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103143_b0180","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2026.103143_b0185","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jamaoncol.2017.2140","article-title":"Association between Genomic Metrics and Immune Infiltration in Triple-negative Breast Cancer","volume":"3","author":"Karn","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0190","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","article-title":"Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy","volume":"1","author":"Samstein","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0195","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and nab-Paclitaxel in Advanced Triple-negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study","volume":"113","author":"Emens","year":"2021","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103143_b0200","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41523-023-00543-0","article-title":"Immune landscape of breast tumors with low and intermediate estrogen receptor expression","volume":"9","author":"Voorwerk","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1015388","article-title":"Clinical implication of low estrogen receptor (ER-low) expression in breast cancer","volume":"13","author":"Reinert","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ctrv.2026.103143_b0215","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-022-00448-4","article-title":"Impact of low versus negative estrogen\/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer","volume":"8","author":"Yoder","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0220","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.2025.43.16_suppl.1071","article-title":"Differential genomic landscape of estrogen receptor (ER)-low versus ER-positive (ER+) and ER-negative (ER-) metastatic breast cancer (MBC)","volume":"43","author":"Corti","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0225","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.annonc.2021.08.1988","article-title":"Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort","volume":"32","author":"Schrodi","year":"2021","journal-title":"Ann Oncol"},{"issue":"148","key":"10.1016\/j.ctrv.2026.103143_b0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2021.02.020","article-title":"Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - an analysis of 2765 patients from neoadjuvant clinical trials","volume":"1990","author":"Villegas","year":"2021","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctrv.2026.103143_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100289","article-title":"The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis","volume":"6","author":"Paakkola","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103143_b0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41523-021-00308-7","article-title":"Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant\/adjuvant chemotherapy","volume":"7","author":"Dieci","year":"2021","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0245","article-title":"Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a swedish population-based cohort study","volume":"40","author":"Acs","year":"2024","journal-title":"Lancet Reg Health \u2013 Eur"},{"key":"10.1016\/j.ctrv.2026.103143_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105907","article-title":"PROMENADE: pembrolizumab for early ER-low\/HER2-negative breast cancer, real-world French cohort","volume":"10","author":"Cherifi","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103143_b0255","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO-24-02263","article-title":"Endocrine Therapy Omission in Estrogen Receptor\u2013Low (1%-10%) Early-Stage Breast Cancer","volume":"43","author":"Choong","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0260","unstructured":"Estrogen receptor expression in residual breast cancer following neoadjuvant chemotherapy. J. Clin. Oncol."},{"key":"10.1016\/j.ctrv.2026.103143_b0265","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104122","article-title":"Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?","volume":"10","author":"Sugiyama","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103143_b0280","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of Residual Breast Cancer Burden to Predict Survival after Neoadjuvant Chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0285","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin. Cancer Res","volume":"26","author":"Spring","year":"2020","journal-title":"Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0290","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-Term Prognostic Risk after Neoadjuvant Chemotherapy Associated with Residual Cancer Burden and Breast Cancer Subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0295","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0300","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 \u2606","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0305","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.44517","article-title":"Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in patients with Early-Stage Breast Cancer","volume":"6","author":"Roy","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctrv.2026.103143_b0310","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1001\/jamaoncol.2024.3679","article-title":"Heterogeneity of Residual Disease after Neoadjuvant Systemic Therapy in Breast Cancer: a Review","volume":"10","author":"Tarantino","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0315","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/s41467-025-57988-z","article-title":"Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103143_b0320","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/annonc\/mdy547","article-title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy","volume":"30","author":"Luen","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100502","article-title":"An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy","volume":"7","author":"Blaye","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103143_b0330","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-RF2-01","article-title":"Abstract RF2-01: Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) - a Pooled Analysis from nine Neoadjuvant GBG\/AGO-B Trials","volume":"32","author":"Holtschmidt","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0335","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.21.01657","article-title":"BRE12-158: a Postneoadjuvant, Randomized phase II Trial of Personalized Therapy Versus Treatment of Physician\u2019s Choice for patients with Residual Triple-negative Breast Cancer","volume":"40","author":"Schneider","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0340","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103143_b0345","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamaoncol.2022.3755","article-title":"Surrogacy of Pathologic complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: critical Analysis of Strengths, Weaknesses, and Misinterpretations","volume":"8","author":"Conforti","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0350","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ctrv.2026.103143_b0355","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","article-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28","volume":"23","author":"Mamounas","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0360","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0370","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008298 women with early breast cancer in 26 randomised trials","volume":"393","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ctrv.2026.103143_b0375","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41523-024-00675-x","article-title":"GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer","volume":"10","author":"M\u00f6bus","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0380","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdx690","article-title":"Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial","volume":"29","author":"M\u00f6bus","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0385","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2015.60.9271","article-title":"Long-Term Follow-up of the E1199 phase III Trial evaluating the Role of Taxane and Schedule in Operable Breast Cancer","volume":"33","author":"Sparano","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0390","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0395","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO-25-01023","article-title":"Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-negative Breast Cancer: a phase III Randomized Controlled Trial","volume":"44","author":"Gupta","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0400","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.breast.2022.04.006","article-title":"Moment of truth-adding carboplatin to neoadjuvant\/adjuvant chemotherapy in triple negative breast cancer improves overall survival: an individual participant data and trial-level Meta-analysis","volume":"64","author":"Pathak","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2026.103143_b0410","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-RF2-02","article-title":"Abstract RF2-02: Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer","volume":"32","author":"Felsheim","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0415","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.61639","article-title":"Genetic Alterations, Therapy Response, and Survival among patients with Triple-negative Breast Cancer: a Secondary Analysis of a Randomized Clinical Trial","volume":"8","author":"Richters","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctrv.2026.103143_b0420","unstructured":"NRG-BR003: A randomized phase III trial comparing...\u00a0: Journal of Clinical Oncology Ovid. https:\/\/www.ovid.com\/journals\/jclon\/fulltext\/10.1200\/jco.2025.43.17_suppl.lba509\u223cnrg-br003-a-randomized-phase-iii-trial-comparing-doxorubicin."},{"key":"10.1016\/j.ctrv.2026.103143_b0425","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103143_b0430","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-021-07791-y","article-title":"The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis","volume":"21","author":"Huo","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0435","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103143_b0440","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.00976","article-title":"Randomized phase III Postoperative Trial of Platinum-based Chemotherapy Versus Capecitabine in patients with Residual Triple-negative Breast Cancer following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131","volume":"39","author":"Mayer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0445","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0450","article-title":"Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-negative Breast Cancer: a Systematic Review and Meta-Analysis","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0455","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0460","doi-asserted-by":"crossref","unstructured":"Abstract GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer: | Clinical Cancer Research | American Association for Cancer Research https:\/\/aacrjournals.org\/clincancerres\/article\/31\/12_Supplement\/GS1-09\/752417\/Abstract-GS1-09-OlympiA-A-phase-3-multicenter.","DOI":"10.1158\/1557-3265.SABCS24-GS1-09"},{"key":"10.1016\/j.ctrv.2026.103143_b0465","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-021-00240-w","article-title":"Cisplatin +\/\u2212 rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer","volume":"7","author":"Kalra","year":"2021","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0470","doi-asserted-by":"crossref","unstructured":"Rugo, H.S., Olopade, O.I., DeMichele, A., Yau, C., van \u2019t Veer, L.J., Buxton, M.B., Hogarth, M., Hylton, N.M., Paoloni, M., Perlmutter, J., et al. (2016). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N. Engl. J. Med. 375, 23\u201334. Doi: 10.1056\/NEJMoa1513749.","DOI":"10.1056\/NEJMoa1513749"},{"key":"10.1016\/j.ctrv.2026.103143_b0475","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","article-title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","volume":"19","author":"Loibl","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0480","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","article-title":"The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer","volume":"629","author":"Abraham","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103143_b0485","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-GS3-01","volume":"31","author":"Turner","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0490","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0495","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival after Neoadjuvant Chemotherapy with or without Carboplatin and Bevacizumab in Triple-negative Breast Cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0500","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/annonc\/mdx173","article-title":"Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial","volume":"28","author":"Earl","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0505","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/annonc\/mdu455","article-title":"Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)\u2020","volume":"25","author":"von Minckwitz","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0510","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(15)00041-8","article-title":"Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial","volume":"16","author":"Bear","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0515","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/annonc\/mdw665","article-title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","volume":"28","author":"Bell","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0520","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1200\/JCO.2018.79.2028","article-title":"Double-blind phase III Trial of Adjuvant Chemotherapy with and without Bevacizumab in patients with Lymph Node-positive and High-Risk Lymph Node-negative Breast Cancer (E5103)","volume":"36","author":"Miller","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0525","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/BCTT.S293597","article-title":"Targeted Treatment for High-Risk Early-Stage Triple-negative Breast Cancer: Spotlight on Pembrolizumab","volume":"14","author":"Bagegni","year":"2022","journal-title":"Breast Cancer Targets Ther"},{"key":"10.1016\/j.ctrv.2026.103143_b0530","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103143_b0535","doi-asserted-by":"crossref","unstructured":"Daniels, E., McKeon, J., Halstead, A., Machado, C. de O., Potter, S., Strawson-Smith, T., Okines, A., McIntosh, S.A., Tovey, H., and Robinson, T. (2025). 204P UK real-world-evidence (RWE) on pembrolizumab (P) and neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC). ESMO Open 10. Doi: 10.1016\/j.esmoop.2025.104758.","DOI":"10.1016\/j.esmoop.2025.104758"},{"key":"10.1016\/j.ctrv.2026.103143_b0540","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103143_b0545","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1245\/s10434-024-16390-7","article-title":"Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-negative Breast Cancer","volume":"32","author":"Connors","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0550","unstructured":"Pembrolizumab for Early Triple-Negative Breast Cancer | New England Journal of Medicine https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1910549."},{"key":"10.1016\/j.ctrv.2026.103143_b0555","unstructured":"Patel, A., Roy, A.M., Alharbi, M., Held, N., Chakraborty, A., Catalfamo, K., Attwood, K., Chaudhary, L.N., Shaikh, S.S., and Gandhi, S. (2025). 7 Real-World Efficacy and Adverse Events of Neoadjuvant Immunotherapy in Early-Stage Triple-Negative Breast Cancer Patients: A Multicenter Experience | CancerNetwork. https:\/\/www.cancernetwork.com\/view\/7-real-world-efficacy-and-adverse-events-of-neoadjuvant-immunotherapy-in-early-stage-triple-negative-breast-cancer-patients-a-multicenter-experience."},{"key":"10.1016\/j.ctrv.2026.103143_b0560","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1016\/j.annonc.2024.08.181","article-title":"238MO PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort","volume":"35","author":"Cherifi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0565","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41523-024-00676-w","article-title":"Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer","volume":"10","author":"Bonadio","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103143_b0570","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.ctrv.2026.103143_b0575","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/s41591-025-03725-4","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","volume":"31","author":"Mittendorf","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103143_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101571","volume":"8","author":"Barrios","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103143_b0585","doi-asserted-by":"crossref","first-page":"S1149","DOI":"10.1016\/j.annonc.2023.09.1260","article-title":"2232O Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031","volume":"34","author":"Harbeck","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0590","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic complete Response in Women with Early-Stage Breast Cancer: an Analysis of the Ongoing phase 2 Adaptively Randomized I-SPY2 Trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0595","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103143_b0600","first-page":"00925","article-title":"A-BRAVE trial: a phase 3 randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients","volume":"S0923\u20137534","author":"Conte","year":"2025","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0605","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0610","unstructured":"Dieci, M.V., Bisagni, G., Nicol\u00e9, L., Schmid, P., Zambelli, A., Piacentini, F., Favaretto, A., Bianchi, G.V., Mion, M., Ferro, A., et al. 323MO Efficacy of adjuvant anti-PD-L1 avelumab by tumor infiltrating lymphocytes (TILs) for high-risk triple-negative breast cancer in the phase III A-BRAVE trial."},{"key":"10.1016\/j.ctrv.2026.103143_b0615","doi-asserted-by":"crossref","first-page":"S1258","DOI":"10.1016\/j.annonc.2023.10.009","article-title":"LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane\/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study","volume":"34","author":"Gianni","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0620","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1186\/s12967-025-06786-8","article-title":"Spatial profiling reveals unique immune microenvironment in premenopausal triple-negative breast cancer associated with therapy response","volume":"23","author":"Nimbalkar","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2026.103143_b0625","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0630","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41586-024-08276-1","article-title":"The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy","volume":"637","author":"Bornes","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103143_b0635","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1016\/j.annonc.2025.08.721","article-title":"292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): long-term analysis from the GeparNuevo trial","volume":"36","author":"Loibl","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0640","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2024.10.012","article-title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","volume":"36","author":"Mart\u00edn","year":"2025","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0645","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13058-025-01986-y","article-title":"Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis","volume":"27","author":"Zhang","year":"2025","journal-title":"Breast Cancer Res BCR"},{"key":"10.1016\/j.ctrv.2026.103143_b0650","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103143_b0655","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-02934","article-title":"The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease","author":"Hunter","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0660","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-negative Breast Cancer: NeoPACT phase 2 Clinical Trial","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0665","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab\u2013deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103143_b0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103143_b0675","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jama.2024.26886","article-title":"Adjuvant Atezolizumab for Early Triple-negative Breast Cancer: the ALEXANDRA\/IMpassion030 Randomized Clinical Trial","volume":"333","author":"Ignatiadis","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2026.103143_b0680","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0685","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.annonc.2023.09.556","article-title":"379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Updated results from BEGONIA, a phase Ib\/II study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0690","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2021.39.15_suppl.1023","article-title":"BEGONIA: phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple-negative breast cancer (TNBC)\u2014Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd)","volume":"39","author":"Schmid","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0695","article-title":"Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic hormone receptor-negative (HR\u2212), HER2-low breast cancer: updated results from BEGONIA, a phase 1b\/2 study","volume":"83","author":"Schmid","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0700","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2025.43.16_suppl.511","article-title":"A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG\/P) in patients with early-stage triple-negative breast cancer: results from the NeoSTAR trial","volume":"43","author":"Abelman","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102238","article-title":"Moving to ultra-short therapy to cure patients with cancer: a solution for sustainable cancer care","volume":"9","author":"Ribeiro","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103143_b0710","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13063-025-08726-9","article-title":"A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)","volume":"26","author":"Arora","year":"2025","journal-title":"Trials"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103143_b0715","first-page":"06335","article-title":"A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC)","volume":"S0923\u20137534","author":"Arora","year":"2025","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0720","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.3390\/ijms25147517","article-title":"Immunotherapy in Breast Cancer","volume":"25","author":"Dvir","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103143_b0725","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.it.2019.02.002","article-title":"The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy","volume":"40","author":"Paucek","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ctrv.2026.103143_b0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J. Hematol. Oncol","volume":"17","author":"Wei","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2026.103143_b0735","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1078-0432.CCR-22-3640","article-title":"New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads. Clin. Cancer Res","volume":"29","author":"Pommier","year":"2023","journal-title":"Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0740","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of Resistance to Antibody-Drug Conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103143_b0745","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103143_b0750","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2026.103143_b0755","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), enhances Antitumor Immunity in a Mouse Model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2026.103143_b0760","doi-asserted-by":"crossref","unstructured":"Schmid, P., Loi, S., Merino, L.D. la C., Yerushalmi, R., Im, S.-A., Sonnenblick, A., Garcia, M.M., Candilejo, I.M., Kennedy, L.C., Griffiths, K.L., et al. (2024). 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC). ESMO Open 9. Doi: 10.1016\/j.esmoop.2024.103203.","DOI":"10.1016\/j.esmoop.2024.103203"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:44:24Z","timestamp":1781059464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":152,"alternative-id":["S0305737226000575"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103143","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress toward personalized management of stage II\/III triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103143"}}